2006
DOI: 10.1080/02813430500475365
|View full text |Cite
|
Sign up to set email alerts
|

Why do sales of lipid-lowering drugs vary between counties in Norway?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
7
0

Year Published

2007
2007
2012
2012

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(8 citation statements)
references
References 14 publications
1
7
0
Order By: Relevance
“…They found that the number needed to treat (NNT) in order to prevent one death from CVD varied substantially between the guidelines. Studies show large variations in use of LLD across Europe [29], between Norwegian counties [30], and within selected population [31,32]. Variations in morbidity may explain only some of the differences [30].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…They found that the number needed to treat (NNT) in order to prevent one death from CVD varied substantially between the guidelines. Studies show large variations in use of LLD across Europe [29], between Norwegian counties [30], and within selected population [31,32]. Variations in morbidity may explain only some of the differences [30].…”
Section: Discussionmentioning
confidence: 99%
“…Studies show large variations in use of LLD across Europe [29], between Norwegian counties [30], and within selected population [31,32]. Variations in morbidity may explain only some of the differences [30]. Reimbursement systems, national guidelines, and drug marketing probably play important roles, as do patients' and physicians' attitudes and preferences.…”
Section: Discussionmentioning
confidence: 99%
“…Ideally, geographical variations of statin consumption should reflect variations in the size of population eligible for such therapy, as defined by the guidelines. However, according to our previous findings in a population-based study from Hedmark and Oppland, the presence of cardiovascular morbidity and risk factors were similar in the populations in the two counties [ 4 ]. Still our previous study indicated that more people received statins for primary prevention in the high-consumption county Hedmark.…”
Section: Introductionmentioning
confidence: 75%
“…Still our previous study indicated that more people received statins for primary prevention in the high-consumption county Hedmark. In addition, the statin users in the primary prevention subgroup seemed to be treated more intensively, as reflected in the higher attainment of total cholesterol (TC) targets among statin users in Hedmark [ 4 ]. The success in achieving the TC target might, however, be influenced by the use of higher dosages of statins and/or continuity of use.…”
Section: Introductionmentioning
confidence: 99%
“…In 2000 -2003 The National Health Screening Service (part of the Norwegian Institute of Public Health since 2002) performed multi-purpose health examination surveys in five counties in Norway: Oslo [8] (the capital, urban south), Oppland, Hedmark [9] (towns and rural areas, south), Troms and Finnmark [10] (towns and rural areas, north). The surveys included questionnaires and objective measurements.…”
Section: The Health Surveysmentioning
confidence: 99%